Huiling Pei

2.5k total citations
42 papers, 620 citations indexed

About

Huiling Pei is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Huiling Pei has authored 42 papers receiving a total of 620 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Hematology, 15 papers in Oncology and 13 papers in Molecular Biology. Recurrent topics in Huiling Pei's work include Multiple Myeloma Research and Treatments (30 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Peptidase Inhibition and Analysis (8 papers). Huiling Pei is often cited by papers focused on Multiple Myeloma Research and Treatments (30 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Peptidase Inhibition and Analysis (8 papers). Huiling Pei collaborates with scholars based in United States, France and Spain. Huiling Pei's co-authors include Ludwig Merker, Éric Renard, Ann Marie Ocampo Francisco, David Russell‐Jones, Simon Heller, Satish K. Garg, Areti Philotheou, Miles Fisher, John B. Buse and Bruce W. Bode and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Huiling Pei

39 papers receiving 596 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Huiling Pei United States	11	309	202	195	182	147	42	620
H. C. Van Paassen Netherlands	11	58 0.2×	62 0.3×	62 0.3×	136 0.7×	247 1.7×	12	616
SM Shalet United Kingdom	12	221 0.7×	67 0.3×	16 0.1×	177 1.0×	75 0.5×	18	687
Maja Barbalić Croatia	12	96 0.3×	35 0.2×	104 0.5×	81 0.4×	22 0.1×	28	453
Jihyun Kwon South Korea	13	33 0.1×	68 0.3×	84 0.4×	163 0.9×	200 1.4×	51	578
S Zecca Italy	6	105 0.3×	89 0.4×	60 0.3×	97 0.5×	18 0.1×	6	412
Nicoletta Masera Italy	14	88 0.3×	23 0.1×	236 1.2×	108 0.6×	13 0.1×	37	547
Xuerui Tan China	8	40 0.1×	38 0.2×	45 0.2×	74 0.4×	33 0.2×	17	333
Rachel Rogers United States	7	126 0.4×	30 0.1×	59 0.3×	76 0.4×	87 0.6×	10	278
B. Leheup France	11	85 0.3×	66 0.3×	38 0.2×	126 0.7×	16 0.1×	29	372
Jennifer Hanson United States	6	23 0.1×	39 0.2×	30 0.2×	92 0.5×	80 0.5×	14	425

Countries citing papers authored by Huiling Pei

Since Specialization

Citations

This map shows the geographic impact of Huiling Pei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Huiling Pei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Huiling Pei more than expected).

Fields of papers citing papers by Huiling Pei

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Huiling Pei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Huiling Pei. The network helps show where Huiling Pei may publish in the future.

Co-authorship network of co-authors of Huiling Pei

This figure shows the co-authorship network connecting the top 25 collaborators of Huiling Pei. A scholar is included among the top collaborators of Huiling Pei based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Huiling Pei. Huiling Pei is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nooka, Ajay K., Jonathan L. Kaufman, César A. Rodríguez, et al.. (2024). Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study. British Journal of Haematology. 204(6). 2227–2232.

Anderson, Larry D., Alfred Chung, Chakra P. Chaulagain, et al.. (2024). Daratumumab Plus Lenalidomide (D-R) Versus Lenalidomide (R) Alone As Maintenance Therapy in Newly Diagnosed Multiple Myeloma (NDMM) after Transplant: Analysis of the Phase 3 Auriga Study Among Clinically Relevant Subgroups. Blood. 144(Supplement 1). 675–675. 1 indexed citations

Moreau, Philippe, Thierry Façon, Saad Z. Usmani, et al.. (2022). OAB-039: Treatment duration and long-term outcomes with daratumumab in transplant-ineligible newly diagnosed multiple myeloma from the phase 3 MAIA study. Clinical Lymphoma Myeloma & Leukemia. 22. S23–S24.

Jakubowiak, Andrzej, Shaji Kumar, Huiling Pei, et al.. (2022). Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma. The Oncologist. 27(7). e589–e596. 12 indexed citations

Rodríguez, Carlos J., Jonathan L. Kaufman, Jacob P. Laubach, et al.. (2022). P934: DARATUMUMAB + LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: A POST HOC ANALYSIS OF SUSTAINED MINIMAL RESIDUAL DISEASE NEGATIVITY FROM GRIFFIN. HemaSphere. 6. 824–825. 2 indexed citations

Grogan, Martha, Matthew J. Maurer, Ronald Witteles, et al.. (2021). EFFECT OF DARATUMUMAB, BORTEZOMIB, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE ON CARDIAC FUNCTION AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH NEWLY-DIAGNOSED AL AMYLOIDOSIS WITH CARDIAC INVOLVEMENT: RESULTS FROM THE PHASE 3 ANDROMEDA STUDY. Journal of the American College of Cardiology. 77(18). 3304–3304. 1 indexed citations

Cook, Gordon, Alessandro Corso, Matthew Streetly, et al.. (2021). Daratumumab Monotherapy for Relapsed or Refractory Multiple Myeloma: Results of an Early Access Treatment Protocol in Europe and Russia. Oncology and Therapy. 9(1). 139–151. 6 indexed citations

Voorhees, Peter M., Cesar Rodriguez, Brandi Reeves, et al.. (2021). Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN. Blood Advances. 5(4). 1092–1096. 18 indexed citations

Wechalekar, Ashutosh, Giovanni Palladini, Giampaolo Merlini, et al.. (2020). Rapid and Deep Hematologic Responses Are Associated with Improved Major Organ Deterioration Progression-Free Survival in Newly Diagnosed AL Amyloidosis: Results from Andromeda. Blood. 136(Supplement 1). 6–7. 5 indexed citations

10.

Usmani, Saad Z., María‐Victoria Mateos, Vânia Hungria, et al.. (2020). Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results. Journal of Cancer Research and Clinical Oncology. 147(2). 619–631. 20 indexed citations

11.

Crusoé, Edvan de Queiroz, et al.. (2020). Results of the daratumumab monotherapy early access treatment protocol in patients from Brazil with relapsed or refractory multiple myeloma. Hematology Transfusion and Cell Therapy. 43(4). 417–423. 5 indexed citations

12.

Weisel, Katja, Pieter Sonneveld, María‐Victoria Mateos, et al.. (2019). Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients (pts) with Multiple Myeloma (MM): Four-Year Update of Castor. Blood. 134(Supplement_1). 3192–3192. 26 indexed citations

13.

Kaufman, Jonathan L., Saad Z. Usmani, Jesús F. San Miguel, et al.. (2019). Four-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM). Blood. 134(Supplement_1). 1866–1866. 28 indexed citations

14.

Cook, Gary, Alessandro Corso, Matthew Streetly, et al.. (2019). PS1425 RESULTS OF THE DARATUMUMAB MONOTHERAPY EARLY ACCESS TREATMENT PROTOCOL (EAP) IN PATIENTS FROM EUROPE AND RUSSIA WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA. HemaSphere. 3(S1). 656–656. 2 indexed citations

15.

Mathews, Maju, Huiling Pei, Adam Savitz, et al.. (2018). Paliperidone Palmitate 3-Monthly Versus 1-Monthly Injectable in Patients With Schizophrenia With or Without Prior Exposure to Oral Risperidone or Paliperidone: A Post Hoc, Subgroup Analysis. Clinical Drug Investigation. 38(8). 695–702. 5 indexed citations

16.

Avet‐Loiseau, Hervé, Jianming He, Katharine S. Gries, et al.. (2018). The Relationship between Minimal Residual Disease and Patient Reported Outcomes in Relapsed/Refractory Multiple Myeloma. Blood. 132(Supplement 1). 3273–3273. 1 indexed citations

17.

Shore, Neal D., Daniel R. Saltzstein, Paul Sieber, et al.. (2018). Real-world study of enzalutamide and abiraterone acetate (with prednisone) tolerability (REAAcT): Results.. Journal of Clinical Oncology. 36(6_suppl). 296–296. 9 indexed citations

18.

Voorhees, Peter M., Cesar Rodriguez, Brandi Reeves, et al.. (2018). Efficacy and Updated Safety Analysis of a Safety Run-in Cohort from Griffin, a Phase 2 Randomized Study of Daratumumab (Dara), Bortezomib (V), Lenalidomide (R), and Dexamethasone (D; Dara‐Vrd) Vs. Vrd in Patients (Pts) with Newly Diagnosed (ND) Multiple Myeloma (MM) Eligible for High‐Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT). Blood. 132(Supplement 1). 151–151. 32 indexed citations

19.

Voorhees, Peter M., Luciano J. Costa, Brandi Reeves, et al.. (2017). Interim Safety Analysis of a Phase 2 Randomized Study of Daratumumab (Dara), Lenalidomide (R), Bortezomib (V), and Dexamethasone (d; Dara-Rvd) Vs. Rvd in Patients (Pts) with Newly Diagnosed Multiple Myeloma (MM) Eligible for High‐Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT). Blood. 130. 1879–1879. 3 indexed citations

20.

Heller, Simon, John B. Buse, Miles Fisher, et al.. (2012). Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. The Lancet. 379(9825). 1489–1497. 309 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact